NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


SEARCH JOBS

View Clinical Trials from BioPharm Insight

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate. As a result of this partnership with Merck, which was announced in July 2007, ARIAD received an up-front investment of $75 million which was rapidly followed by a $13.5 million milestone payment for the launch of the phase 3 trial in September 2007. Medinol Ltd. also is developing stents and other medical devices that deliver deforolimus to prevent reblockage at sites of vascular injury following stent-assisted angioplasty. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity, which may be useful in treating certain diseases.

Additional information about ARIAD can be found on the web at http://www.ariad.com.

Pathways to Success

ARIAD's success depends on talented and experienced people who are dedicated to driving success in developing better cancer therapies. If you welcome challenge and thrive on opportunity, we strongly encourage you to consider a career at ARIAD.

Mission & Vision

ARIAD’s mission is to provide cancer patients with significantly better treatment options. Based on our expertise in the regulation of cell signaling, we are developing and commercializing breakthrough therapies for a broad range of cancers. The success of our development programs is moving us closer to realizing our vision of becoming a fully integrated oncology company addressing unmet needs with new molecularly targeted therapies and improving the lives of cancer patients throughout the world.

Values

Teamwork: The atmosphere at ARIAD is one of collaboration and support. Effective teamwork requires close cooperation and a willingness to listen.
An Entrepreneurial Spirit: At ARIAD, we value the contribution of dedicated individuals who have ambition, a need to create, and a willingness to take calculated risks.
Excellence: We provide unique opportunities for motivated people who value personal and professional growth and want to achieve their full potential.
Creativity: Ours is a fast-moving business where success demands fresh thinking and creative problem solving.
Mutual respect: Through an atmosphere of mutual respect, we create an environment that nurtures confidence and trust.

Last Updated: 12-19-2007

 Key Statistics


Email:
Ownership:
Web Site: Ariad Pharmaceuticals, Inc.
Employees:
Symbol: ARIA
 









 Company News
Ariad Pharmaceuticals, Inc. (ARIA) to Present at the Lazard Capital Markets 6th Annual Healthcare Conference 11/10/2009 9:35:17 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) Reports Third Quarter 2009 Development Progress and Financial Results 11/5/2009 9:17:57 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA)'s AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor 11/2/2009 10:05:34 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) to Present at the Oppenheimer 20th Annual Healthcare Conference 10/27/2009 9:55:55 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) to Webcast Conference Call on Third Quarter 2009 Financial Results 10/22/2009 9:25:27 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) Announces Clinical Data from Phase 1 Study of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Bevacizumab 9/21/2009 9:29:01 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) (JOBS) Says Independent Experts Positive on Cancer Drug 9/14/2009 10:06:55 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) to Present at the Rodman & Renshaw Annual Healthcare Conference 9/2/2009 10:01:09 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) And Its Co-Plaintiffs Announce That the Court of Appeals Granted Their Petition for Rehearing En Banc In the Eli Lilly and Company (LLY) NF-kB Patent Lawsuit 8/24/2009 9:24:10 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) Announces Completion of Public Offering of Common Stock and Full Exercise of Over-Allotment Option 8/7/2009 12:20:12 PM    More...
12345678910...